CA-ESRI
23.3.2021 14:43:09 CET | Business Wire | Press release
Esri , the global leader in location intelligence, today announced that the Emirates Real Estate Solutions (ERES) land development and land market services and Khatib & Alami (K&A) will use Esri's ArcGIS system to geoenable ERES solutions and service offerings to the international land development and real estate market.
By incorporating Esri's capabilities for field collection, spatial analytics, and mapping into the ERES infrastructure and solutions, ERES can now provide real-time data like valuable locations, sales assessments, and rent indexes. This allows investors and regulators to establish equitable valuation and property taxation through embedded dashboards and maps that provide an instant view of the real estate development market from any device, anywhere, and anytime.
In the early 2000s, the government of Dubai initiated a financial transition to become service and tourism oriented, allowing foreign investors to buy freehold properties, helping the city become a center for investment. To encourage and support this, ERES developed a suite of solutions and in the process gained expertise in providing technology and services to ensure secure and efficient real estate investments.
"ERES is pleased to have inked this agreement with Esri and K&A, both of whom are prime leaders in cadastre solutions and the land survey domain," said Khalifa Al Suwaidi, ERES CEO and board member. "ERES' vision [for] unique and present intellectual property products and experiences [is] to . . . grow and bring all solutions to the bigger market . . . of real estate."
An urban and regional planning, architectural, and engineering consulting company, as well as an Esri platinum partner, K&A brings decades of successful deployment throughout the Middle East, Central Asia, and Africa. The firm is also specifically qualified to help governments and other real estate entities deploy the ERES platform and build local capacity to maintain, operate, and expand its solutions over time.
"We are pleased to collaborate with Esri and ERES in this vital initiative, which provides stakeholders in the UAE's real estate industry with innovative IT solutions, adding more efficiency and transparency to the marketplace," said Faisal Alami, K&A executive vice president. "Our vast experience as a leading geospatial systems integrator will help us bring new levels of visibility and understanding for real estate investors, which will support their decision-making and ultimately drive confidence and growth in the sector."
"Digital transformation is happening around the world at unprecedented rates, and geospatial data is now foundational for most businesses and governments," said Sohail Elabd, director of Esri Middle East and Africa. "The ERES geospatial platform is a unique project that brings geospatial technology to real estate on a tremendous scale for the first time in the Middle East and Africa."
This collaboration around a geographic information system (GIS)-based real estate solution will provide governments, investors, developers, real estate agents, and property owners with a unique and highly adaptable software infrastructure, which can help drive and sustain economies centered around the land market.
To learn more about the new ERES platform, visit eres.ae .
About K&A
Khatib & Alami (K&A) is an international multidisciplinary consultancy composed of architects, engineers, planners, technologists and other project specialists. With 6,000 people in more than 30 locations, K&A has vast experience working at the forefront of fast changing urban environments, with a deep understanding of delivering complex major projects within agreed time frames and budgets.
Since launching its Geospatial Systems Integration division in 1988, K&A has become among the leaders in its field, with a 200-strong team of GIS experts. K&A helps government and private sector clients make sense of the vast quantities of information and data available to them, providing insight, enabling better decision-making, creating efficiencies, and improving customer experiences. As an Esri platinum partner, K&A continuously provides innovative smart solutions that address business challenges and exceed customers' expectations. For more information visit www.khatibalami.com .
About Esri
Esri, the global market leader in geographic information system (GIS) software, location intelligence, and mapping, helps customers unlock the full potential of data to improve operational and business results. Founded in 1969 in Redlands, California, USA, Esri software is deployed in more than 350,000 organizations globally and in over 200,000 institutions in the Americas, Asia and the Pacific, Europe, Africa, and the Middle East, including Fortune 500 companies, government agencies, nonprofits, and universities. Esri has regional offices, international distributors, and partners providing local support in over 100 countries on six continents. With its pioneering commitment to geospatial information technology, Esri engineers the most innovative solutions for digital transformation, the Internet of Things (IoT), and advanced analytics. Visit us at esri.com .
Copyright © 2021 Esri. All rights reserved. Esri, the Esri globe logo, ArcGIS, The Science of Where, esri.com, and @esri.com are trademarks, service marks, or registered marks of Esri in the United States, the European Community, or certain other jurisdictions. Other companies and products or services mentioned herein may be trademarks, service marks, or registered marks of their respective mark owners.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210323005747/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release
Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom